Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions
- 1 January 1998
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 20 (1) , 2-25
- https://doi.org/10.1016/s0149-2918(98)80031-3
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- LamivudineDrugs, 1997
- In vitro protein-binding characteristics of delavirdine and its N-dealkylated metaboliteAntiviral Research, 1996
- SaquinavirDrugs, 1996
- Current Knowledge and Future Prospects for the Use of HIV Protease InhibitorsDrugs, 1996
- Evaluation of Safety and Efficacy of 3TC (Lamivudine) in Patients with Asymptomatic or Mildly Symptomatic Human Immunodeficiency Virus Infection: A Phase I/II StudyThe Journal of Infectious Diseases, 1995
- A Randomized Pilot Study of Alternating or Simultaneous Zidovudine and Didanosine Therapy in Patients with Symptomatic Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994
- Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitory Interactions between Protease Inhibitor Ro 31-8959 and Zidovudine, 2',3'-Dideoxycytidine, or Recombinant Interferon- A against Zidovudine-Sensitive or -Resistant HIV-1 In VitroThe Journal of Infectious Diseases, 1992
- HIV Drug ResistanceAIDS Research and Human Retroviruses, 1992
- Comparative Studies of 2′,3′‐Didehydro‐2′,3′‐Dideoxythymidine (D4T) with other Pyrimidine Nucleoside AnaloguesAnnals of the New York Academy of Sciences, 1990
- Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related DisordersThe Journal of Clinical Pharmacology, 1988